KDR and neoplasm: Sunitinib malate (SU011248) is an orally bioavailable receptor tyrosine kinase inhibitor that antagonizes cellular signaling of multiple targets involved in tumor proliferation and angiogenesis, with specific activity against VEGFR, PDGFR, KIT, and Fms‐like tyrosine kinase 3 receptor 5.